Prevalence and outcomes of cryptococcal antigenemia in HIV-seropositive patients hospitalized for suspected tuberculosis in uganda

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 2, 2013, Pages 189-194

  Andama, Alfred O ^a,b,c   Den Boon, Saskia ^a   Meya, David ^b,c,h   Cattamanchi, Adithya ^d   Worodria, William ^a,b,c   Davis, J Lucian ^d   Walter, Nicholas D ^e   Yoo, Samuel D ^f   Kalema, Nelson ^a   Haller, Barbara ^g   Huang, Laurence ^d,g  

^a MAKERERE UNIVERSITY   (Uganda)

^b MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^c MULAGO NATIONAL REFERRAL HOSPITAL   (Uganda)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f Health Tutors' College Mulago   (Uganda)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF MINNESOTA   (United States)

Author keywords

AIDS; Antigenemia; Cryptococcus neoformans; HIV; Tuberculosis

Indexed keywords

COTRIMOXAZOLE; FLUCONAZOLE; FUNGUS ANTIGEN;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; COUGHING; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DEMOGRAPHY; DISEASE DURATION; FEMALE; FOLLOW UP; FUNGAL DETECTION; FUNGUS CULTURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SEROPREVALENCE; TUBERCULOSIS; UGANDA; AIDS RELATED COMPLEX; BLOOD; CRYPTOCOCCUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIGENS, FUNGAL; CRYPTOCOCCOSIS; CRYPTOCOCCUS; FEMALE; HIV INFECTIONS; HUMANS; MALE; TUBERCULOSIS; UGANDA;

MLCS; MLOWN;

EID: 84879773812     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182926f95     Document Type: Article

References (17)

1. Park BJ, Wannemuehler KA, Marston BJ, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23:525-530.
2. Mirza SA, Phelan M, Rimland D, et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis. 2003;36:789-794.
3. French N, Gray K, Watera C, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS. 2002;16:1031-1038.
4. Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active anti-retroviral therapy. Clin Infect Dis. 2008;46:1694-1701.
5. Churchyard GJ, Kleinschmidt I, Corbett EL, et al. Factors associated with an increased case-fatality rate in HIV-infected and non-infected South African gold miners with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2000;4:705-712.
6. Yoo SD, Worodria W, Davis JL, et al. The prevalence and clinical course of HIV-associated pulmonary cryptococcosis in Uganda. J Acquir Immune Defic Syndr. 2010;54:269-274.
7. Kyeyune R, den Boon S, Cattamanchi A, et al. Causes of early mortality in HIV-infected TB suspects in an East African referral hospital. J Acquir Immune Defic Syndr. 2010;55:446-450.
8. Meya DB, Munabe YC, Castelnuovo B, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count, or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis. 2010;51:448-455.
9. Kish L. Survey Sampling. New York, NY: John Wiley and Sons, Inc, ; 1965.
10. Jarvis JN, Lawn SD, Vogt M, et al. Screening for cryptococcal antige-nemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis. 2009;48:856-862.
11. Micol R, Lortholary O, Sar B, et al. Prevalence, determinants of positiv-ity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr. 2007;45:555-559.
12. Liechty CA, Solberg P, Were W, et al. Asymptomatic serum cryptococ-cal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health. 2007;12:929-935.
13. Feldmesser M, Harris C, Reichberg S, et al. Serum cryptococcal antigen in patients with AIDS. Clin Infect Dis. 1996;23:827-830.
14. Yuen C, Graziani A, Pietroski N, et al. Cryptococcal antigenemia in HIV-infected patients [abstract no. 93]. Clin Infect Dis. 1994;19:579.
15. Lindsley MD, Mekha N, Baggett HC, et al. Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis. 2011;53:321-325.
16. Uwe KF, Nishimura SL, Li NC, et al. Evaluation of an enzyme immunoassay for detection of cryptococcal capsular polysaccharide antigen in serum and cerebrospinal fluid. J Clin Microbiol. 1993;31: 97-101.
17. Lortholary O, Poizat G, Zeller V, et al. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS. 2006;20:2183-2191.